A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with mutation (West Japan Oncology Group 11719L/ADJUST study)

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with mutation (West Japan Oncology Group 11719L/ADJUST study)

Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is a standard treatment in EGFR- mutated advanced non-small-cell lung cancer (NSCLC); however, previous data have suggested that EGFR-TKI has limited potential as adjuvant therapy. On the contrary, based on subset an...

Full description

Bibliographic Details
Main Authors: Ryota Shibaki, Hiroaki Akamatsu, Terufumi Kato, Kazumi Nishino, Morihito Okada, Tetsuya Mitsudomi, Kazushige Wakuda, Kenichi Yoshimura, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Format: Article
Language:English
Published: SAGE Publishing 2021-01-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920987647

Internet

https://doi.org/10.1177/1758835920987647

Similar Items